Thermo Fisher Scientific (NYSE:TMO) Sets New 12-Month High – Here’s What Happened
by Scott Moore · The Cerbat GemShares of Thermo Fisher Scientific Inc. (NYSE:TMO – Get Free Report) hit a new 52-week high during trading on Tuesday. The stock traded as high as $694.33 and last traded at $678.8880, with a volume of 218570 shares. The stock had previously closed at $676.76.
Thermo Fisher Scientific News Roundup
Here are the key news stories impacting Thermo Fisher Scientific this week:
- Positive Sentiment: New clinical-trial agreement supports PPD growth. Thermo Fisher’s PPD clinical research business signed an agreement with Quantum BioPharma to launch a Phase 2, randomized trial of its Lucid-MS multiple-sclerosis therapy. The deal should provide additional clinical-research revenue and reinforces PPD’s role as a contract research partner for emerging biopharmaceutical companies. Quantum BioPharma Enlists Thermo Fisher’s Clinical Research Business to Launch Phase 2 Lucid-MS Trial
- Positive Sentiment: Expanded drug-development offerings could support demand. At CPHI Milan 2026, Thermo Fisher highlighted new and expanded drug-development, manufacturing and clinical capabilities, including its OSD Express solution. The initiatives are intended to help pharmaceutical and biotechnology customers accelerate commercialization and improve manufacturing predictability, supporting the company’s diversified growth strategy. Thermo Fisher Scientific Showcases New Solutions and Expanded Capabilities
- Positive Sentiment: Investment commentary remains constructive. ClearBridge Investments cited strong third-quarter guidance, broadening end-market demand and Thermo Fisher’s multi-year outlook. Separate analysis also pointed to innovation, acquisitions and exposure to multiple research markets as potential growth drivers. Strong Q3 Guidance and Broadening Demand Support Multi-Year Outlook
- Neutral Sentiment: A market report identified Thermo Fisher as a major participant in the cell-based assay and high-content screening market, where automation, 3D assays and immuno-oncology research are driving demand. The report is industry-wide rather than company-specific, so its direct effect on TMO is limited. Cell-Based Assay and High Content Screening Market Report
- Negative Sentiment: Valuation and macroeconomic risks remain potential restraints. Commentary noted currency exposure and uncertain research spending, while TMO trades at a relatively elevated valuation after reaching a new one-year high. Those factors may encourage profit-taking despite the favorable operating outlook. Is This the Right Time to Add TMO Stock to Your Portfolio?
Analyst Ratings Changes
Several analysts have recently issued reports on the company. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $720.00 price objective on shares of Thermo Fisher Scientific in a report on Friday, September 25th. BMO Capital Markets lowered shares of Thermo Fisher Scientific to a “market perform” rating in a research report on Wednesday, September 9th. Royal Bank Of Canada upped their target price on shares of Thermo Fisher Scientific from $490.00 to $580.00 and gave the company a “sector perform” rating in a research report on Friday, July 24th. Weiss Ratings upgraded Thermo Fisher Scientific from a “hold (c)” rating to a “hold (c+)” rating in a research report on Friday, August 28th. Finally, Stifel Nicolaus set a $650.00 price objective on Thermo Fisher Scientific in a research report on Wednesday, August 5th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and a consensus price target of $635.55.
Read Our Latest Analysis on TMO
Thermo Fisher Scientific Stock Up 0.7%
The business has a fifty day moving average of $624.23 and a 200-day moving average of $539.29. The stock has a market cap of $244.39 billion, a PE ratio of 35.56, a price-to-earnings-growth ratio of 2.75 and a beta of 0.87. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18.
Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last posted its earnings results on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, beating analysts’ consensus estimates of $5.71 by $0.32. The business had revenue of $11.99 billion for the quarter, compared to the consensus estimate of $11.71 billion. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The company’s revenue for the quarter was up 10.5% on a year-over-year basis. During the same quarter last year, the firm posted $4.28 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 25.13 earnings per share for the current year.
Insider Activity
In other news, CAO Joseph R. Holmes sold 420 shares of the stock in a transaction on Friday, August 7th. The stock was sold at an average price of $584.81, for a total transaction of $245,620.20. Following the completion of the sale, the chief accounting officer owned 2,966 shares in the company, valued at approximately $1,734,546.46. This represents a 12.40% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Marc N. Casper sold 275 shares of the stock in a transaction dated Monday, August 24th. The shares were sold at an average price of $627.05, for a total value of $172,438.75. Following the completion of the sale, the chief executive officer owned 123,925 shares of the company’s stock, valued at approximately $77,707,171.25. This trade represents a 0.22% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 73,768 shares of company stock valued at $44,122,820 over the last 90 days. 0.33% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On Thermo Fisher Scientific
A number of institutional investors and hedge funds have recently modified their holdings of the company. Tsfg LLC grew its stake in Thermo Fisher Scientific by 20.4% during the second quarter. Tsfg LLC now owns 112 shares of the medical research company’s stock valued at $56,000 after acquiring an additional 19 shares in the last quarter. Renasant Bank raised its position in Thermo Fisher Scientific by 1.0% during the second quarter. Renasant Bank now owns 1,934 shares of the medical research company’s stock valued at $970,000 after purchasing an additional 20 shares in the last quarter. TCI Wealth Advisors Inc. lifted its stake in Thermo Fisher Scientific by 5.4% during the first quarter. TCI Wealth Advisors Inc. now owns 431 shares of the medical research company’s stock worth $212,000 after purchasing an additional 22 shares during the last quarter. Legacy Wealth Managment LLC ID increased its position in shares of Thermo Fisher Scientific by 78.6% during the 1st quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 22 shares during the last quarter. Finally, Chesapeake Wealth Management boosted its stake in Thermo Fisher Scientific by 0.6% in the second quarter. Chesapeake Wealth Management now owns 3,725 shares of the medical research company’s stock worth $1,868,000 after buying an additional 22 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc is a global provider of laboratory products, analytical instruments, reagents, consumables, software and services. Its offerings support research, drug discovery and development, clinical diagnostics, biotechnology and pharmaceutical manufacturing, as well as environmental, industrial and other applied markets.
The company’s portfolio includes mass spectrometers, genetic analysis and sequencing systems, electron microscopes, chromatography equipment, laboratory plastics, cell culture products, antibodies, protein and molecular biology reagents, and diagnostic testing solutions.